-
公开(公告)号：US09535075B2
公开(公告)日：2017-01-03
申请号：US13635667
申请日：2011-03-25
申请人： Minnie M. Sarwal , Tara Sigdel , Amit Kaushal , Li Li , Wenzhong Xiao , Atul J. Butte , Purvesh Khatri
发明人： Minnie M. Sarwal , Tara Sigdel , Amit Kaushal , Li Li , Wenzhong Xiao , Atul J. Butte , Purvesh Khatri
CPC分类号： G01N33/6893 , C12Q1/6809 , C12Q1/6883 , C12Q2600/158 , G01N2800/245
摘要： Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.
摘要翻译： 本发明的方面包括用于确定具有移植物的受试者的移植类别的方法。 排除损伤的常见机制在不同的组织移植中被发现，并且提供了解理性药物设计的手段。 从患者身上检查各种来源的组织，以了解AR机制（移植物活检），以及通过最小侵入性手段（血液）或非侵入性手段（尿同种异体移植物的尿液）进行监测。 对于生物标志物发现，检查不同类别的标记物，例如基因，蛋白质，肽和抗体。 这些生物标志物可以帮助确定受试者的移植类别（例如急性同种异体移植排斥（AR），稳定的同种异体移植物（STA），BK病毒血症，BK肾炎，药物毒性或慢性同种异体移植物损伤（CAI）等）。 还提供了用于实践主题方法的组合物，系统，试剂盒和计算机程序产品。 这些方法和组合物可用于各种应用。
-
公开(公告)号：US20130143755A1
公开(公告)日：2013-06-06
申请号：US13635667
申请日：2011-03-25
申请人： Minnie M. Sarwal , Tara Sigdel , Amit Kaushal , Li Li , Wenzhong Xiao , Atul J. Butte , Purvesh Khatri
发明人： Minnie M. Sarwal , Tara Sigdel , Amit Kaushal , Li Li , Wenzhong Xiao , Atul J. Butte , Purvesh Khatri
CPC分类号： G01N33/6893 , C12Q1/6809 , C12Q1/6883 , C12Q2600/158 , G01N2800/245
摘要： Aspects of the present invention include methods for determining a transplant category of a subject having a transplant. Common mechanisms of rejection injury are uncovered across different tissue transplants, and provide a means to understand rational drug design. Various sources of tissues are examined form the patient for understanding AR mechanism (graft biopsy), as well as monitoring by minimal invasive means (blood) or non-invasive means (urine for the kidney allograft). For biomarker discovery different categories of markers are examined such as genes, proteins, peptides and antibodies. These biomarkers can help determine the subject's transplant category (e.g., acute allograft rejection (AR), stable allograft (STA), BK viremia, BK nephritis, drug toxicity or chronic allograft injury (CAI), and the like). Also provided are compositions, systems, kits and computer program products that find use in practicing the subject methods. The methods and compositions find use in a variety of applications.
摘要翻译： 本发明的方面包括用于确定具有移植物的受试者的移植类别的方法。 排除损伤的常见机制在不同的组织移植中被发现，并且提供了解理性药物设计的手段。 从患者身上检查各种来源的组织，以了解AR机制（移植物活检），以及通过最小侵入性手段（血液）或非侵入性手段（尿同种异体移植物的尿液）进行监测。 对于生物标志物发现，检查不同类别的标记物，例如基因，蛋白质，肽和抗体。 这些生物标志物可以帮助确定受试者的移植类别（例如急性同种异体移植排斥（AR），稳定的同种异体移植物（STA），BK病毒血症，BK肾炎，药物毒性或慢性同种异体移植物损伤（CAI）等）。 还提供了用于实践主题方法的组合物，系统，试剂盒和计算机程序产品。 这些方法和组合物可用于各种应用。
-
搜索结果
2 条记录 (耗时 0.024 秒)